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Under the Direction of Andrew T. Gewirtz, PhD

ABSTRACT
Metabolic Syndrome is a constellation of metabolic abnormalities associated with insulin
resistance and obesity, including hyperglycemia and hypertension. Metabolic syndrome often
progresses to type 2 diabetes, hypertension, cardiovascular disease, and liver disease. Metabolic
syndrome is increasingly appreciated to be an inflammatory disease in that is associated with
increased expression of pro-inflammatory genes and markers, remodeling of adipose tissue, and
markedly increased incidence in the last 50 years. Additionally, both diseases alter the microbiota,
specifically with alteration in gut microbiota composition. Metabolic syndrome requires a
microbiota in that disease is not observed in germ- free mice, and some aspects of the disease can
be transferred by fecal transplant. There is a probable correlation between metabolic disorder and

gut microbiota. It’s also been shown that the efficacy of systemic medications can be affected by
the gut microbiota and that some medications can alter the microbiota. Metformin is believed to
be one of those medications. Accordingly, the results of the present study could be employed to
develop novel methods for treating metabolic syndrome using medications such as metformin.
Furthermore, this study can set the stage for further research towards the application of fecal
transplantation as a treatment strategy for individuals with conditions like metabolic syndrome.
The overall goal of my studies was to investigate this hypothesis.
First, I comprehensively examined the existing gut microbiota literature to discern the
range of treatment of type 2 diabetes mellitus that have been associated with, or attributed to,
changes in microbiota composition. Chapter 1 outlines findings from this effort.
Next, I performed experiments to investigate the extent to which metformin attenuates
metabolic syndrome and inflammation by alternation of intestinal microbiota. My results support
the notion that metformin induces changes in gut microbiota composition. However, such changes
were not necessary for metformin to alleviate parameters of metabolic syndrome indicating that
metformin can, at least in part act independently of gut microbiota. Rather Metformin reduced
indices of inflammation in both conventional germ-free conditions. These results support a role
for metformin’s anti-inflammatory effects rather than its direct action on microbiota for its
beneficial metabolic impacts.

INDEX WORDS: Intestinal microbiota, Obesity, Inflammation, Metabolic Syndrome, type 2
diabetes, treatment
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1 INTRODUCTION
While many consider obesity as a major health concern of the current century, in fact,
existing artwork, even those from the prehistoric and paleothic times, prove obesity is not a new
problem. The statues of Venus of Willendorf from Stone Age show obese silhouettes from 25
thousand years ago. Obesity can also be seen in the Venus of Catalhoyuk (Turkey), representing
a female figure from Neolithic times sitting on a leopard throne. Even the statues of the Mayan
men demonstrate the existence of protuberant abdomen and central adiposity during the Atlantic
Ocean Mesoamerican times (in Central America) (1).
Yet, indeed, prevalence of obesity is rising throughout the world, and thus it is considered
as a global epidemic. According to the International Diabetes Federation (IDF) in 2017, there
were 451 million (age 18-99 years) people with diabetes worldwide (2). This is expected to reach
693 million by 2045. It is also estimated that half of the individuals living with diabetes (49.7%)
remain undiagnosed. In 2017, approximately 5 million adult deaths worldwide were attributed to
diabetes. The global healthcare expenditure on diabetes was estimated to be 850 billion USD in
the same year (3)
Obesity affects health in various aspects, ranging from depression and anxiety to
respiratory problems like sleep apnea and asthma, type 2 diabetes, heart disease, increased risk of
cancer, liver disease, stroke, musculoskeletal complications such as osteoarthritis and back pain
and infertility. Obesity is more common amongst people from more deprived areas of developed
countries, although, in less developed countries, the wealthier class with an easier access to food
are more prone to the condition. It also affects a range of minority ethnic groups
disproportionately.
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1.1

Relationship between Obesity and Diabetes
The ongoing rise in the prevalence of obesity in the United States has been driven, at least

in part, by the availability of cheap, appetizing, and high-calorie foods along with reduced fiber
impacted on gut microbiota (4-5). On the other hand, the close relationship between diabetes and
obesity has been clear and well-documented for the last 50 years. Prevalence of obesity in people
with diabetes varies between 30% and 80%, depending on the ethnicity and geographical region.
While the opposite is not true, as diabetes is not commonly reported among obese individuals.
Statistics show that approximately one in four US adults suffer from obesity. This is while only
one in every 20 of them are diagnosed with diabetes. In other words, approximately 10% of the
obese individuals have diabetes (6).
1.2

A Complex Mechanism based on Inflammation and Microbiome Links Obesity to
Diabetes
Many hypotheses such as 'lipid overflow', 'inflammation', 'adipokine', 'microbiome', and

'brown fat' are reported to explain the mechanism linking obesity to diabetes (7-10). It is
important to highlight that these mechanisms are not necessarily exclusive, as multiple
mechanisms may co-exist and interact, causing obesity in diabetic individuals. Considering the
objectives of the current project, inflammation and microbiome will be discussed in more detail.
The inflammation hypothesis suggests that the accumulation of dysfunctional adipose tissue
leads to 'retained inflammation,' or chronic low-level inflammation in response to positive energy
balance. Many believe white adipose tissue is the main culprit in obesity-related diabetes. The
white adipose tissue is considered as an organ, given its distinct functions such as long-term
energy storage and regulation of metabolism. However, unlike most organs, the white adipose
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tissue can be found in different parts of the body. Different depots of white adipose tissue appear
to have different immuno-phenotypes, metabolic profiles, and differentiation potentials. The two
most significant depots of white adipose tissue are subcutaneous and visceral adipose tissues.
Dysfunctional adipose tissue is mainly found in the visceral fat depots where subcutaneous
adipose tissue is less inflammatory. Adipocyte hypertrophy leads to infiltration and accumulation
of adipose tissue macrophages, which are the critical cells mediating the inflammatory response.
Two main molecules involved in the recruitment of macrophages are monocyte chemotactic
protein 1 (MCP1) and macrophage migratory inhibitory factor (MIF), which respectively attract
macrophages and retain them in the adipose tissue; and thus, are responsible for the
accumulation of high numbers of adipose tissue macrophages, leading to the secretion of proinflammatory cytokines (11).
One of the critical pro-inflammatory cytokines produced in dysfunctional adipose tissue is tumor
necrosis factor-alpha (TNF-,), a well-known cytokine produced by the adipose tissue
macrophages and responsible for an increase insulin resistance in adipose tissue, muscle, and
liver (12). The adipocytes themselves produce interleukin 6 (IL-6), resulting in an increase in
insulin resistance, lipolysis, and thus, a surge in free-fatty acid levels and hepatic glucose output;
these all lead to hyperglycemia (13). Interleukin-1 (IL-1), similar to TNF-, causes insulin
resistance. There appears to be a link between these interleukins as they inhibit the downstream
signal transduction from the insulin receptor, thus, inducing insulin resistance in target cells (14).
Therefore, the induction of lipolysis by IL-6 can amplify the insulin resistance response by
releasing fatty acids.
MCP-1, as previously noted, is expressed at high levels in obesity. Hyperinsulinemia increases
adipocyte expression of MCP-1 in case of insulin resistance, e.g., during diet-induced obesity.

4

Moreover, this attracts macrophages towards adipose tissue, initiating and perpetuating
inflammation. This results in increased insulin resistance in adipocytes, skeletal muscles, and
liver, leading to impaired glucose disposal. Inflammatory cytokines, at the same time, increase
the lipolytic release of free-fatty acids and blood glucose levels via insulin resistance, causing
glucolipotoxicity at the beta-cell level. This is associated with beta-cell apoptosis and impaired
insulin secretion. The combination of insulin resistance and failure to secrete insulin, is
obviously the recipe for diabetes (11).
Over the last few years, mounting evidence has been produced indicating that there exist bacteria
in the gastrointestinal tract known as microbiota, which have a profound effect on health. The
term “microbiota” is used to describe the bacteria residing in the gastrointestinal lumen,
whereas, “microbiome,” is used to describe a collection of genes existing in this bacterial
population. Currently, the bacteria species and their relative proportions in microbiota is defined
through DNA isolation from a stool sample and analyzing the 16s RNA sequences of the various
types of bacteria obtained from the lumen.
Microbiota can influence metabolism through different means. They regulate appetite by
controlling hormones and other mediators, regulating glucose and lipid production in the
gastrointestinal lumen. This changes the patterns of digestion and absorption of nutrients,
regulating inflammatory responses in the body.
The 'microbiome hypothesis’ postulates that in some people, the existence of pro-obesity
microbiota causes obesity and diabetes through different mechanisms such as reducing satiety
feedback signals to the brain, increasing free-fatty acid levels, increasing pro-inflammatory
changes in the liver and adipose tissue, causing alterations in skeletal muscle metabolism, and
finaly degrading the barrier function of the intestinal epithelium. The latter mechanism results in
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the excessive entrance of mediators including pro-inflammatory toxins into the portal
circulation. This inflammatory state also alters the absorption of different nutrients from the food
consumed (15).
There exists solid evidence indicating that obesity is associated with various changes in the
characteristics of the microbiota, such as reduced diversity and altered relative proportions of
different species. It is even demonstrated that obesity is also responsible for some alternations in
the microbiota population, including an increase in the ratio of Firmicutes to Bacteroidetes and in
relative abundance of Proteobacteria (16). One of the main practical applications of the research
carried out in this field, is the provision of new horizons for transplantation of metabolic
phenotypes. For example, in a randomized controlled trial, when transplanted with lean persons'
feces, obese volunteers demonstrated a statistically significant improvement in insulin
sensitivity. It should be noted that despite the promising results, fecal transplantation is not yet
clinically available to patients who may benefit from the procedure (17-18).
In summary, several pieces of evidence have emerged to link obesity to diabetes. Firstly, both
obesity and diabetes affect the same organs such as adipose tissue, pancreas, liver, muscles, and
the brain. Secondly, chronic positive energy balance leads to accumulation of fat in the adipose
(particularly in the visceral fat depot) and peripheral tissues such as liver, muscle, and pancreas.
Thirdly, the chronic low-level inflammatory state caused by obesity leads to insulin resistance,
hyperlipidemia, and accumulation of fat and lipotoxicity in the periphery. Finally, when present,
brown adipose tissue that may play a role in insulin sensitivity can further highlight the
relationship between obesity and diabetes. It should be stated, nonetheless, that all mentioned
mechanisms may coexist, interact, and influence individuals in different proportions.
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1.3

Effect of Metformin on Inflammation and Microbiome

Biguanides, notably metformin, have been used extensively as the first line medication for
treating type 2 diabetes mellitus (DM2) over the past 50 years (19). However, the exact
mechanism(s) of action of metformin, especially those responsible for its numerous reported
health benefits and anti-hyperglycemic properties, are still unknown (19, 20). The UK
Prospective Diabetes Study Group in 1998 reported the survival benefit and cardiovascular
protection of metformin compared to other conventional DM2 treatments, including diet,
sulfonylurea, and insulin (21). In a clinical trial, the consumption of metformin was found to be
advantageous even in patients suffering from renal insufficiency or heart failure who were
historically thought to be at higher risk for the side effects of biguanides, notably lactic acidosis
(22,23).Moreover, several reports recommend metformin over phenformin, the first generation
biguanide, as the former is considered a safe medication with no evidence of lactic acidosis in
non-diabetics, even at old ages (24-26). It is widely accepted that the anti-hyperglycemic
properties of metformin are mainly because of a mild and transient inhibition of the
mitochondrial respiratory-chain complex 1 (27). This increases the level of intracellular activated
protein kinase (AMP) compared to Adenosine triphosphate (ATP). The increase in AMP to ATP
ratio activates AMP-activated protein kinase (AMPK), which switches cells from an anabolic to
a catabolic state. Consequently, glucose, lipid, and protein synthesis are inhibited while the
oxidation of fatty acids and glucose uptake are stimulated (19). This pathway has been confirmed
in several cell types involved directly in metabolism and energy expenditure such as hepatocytes
(28), skeletal muscle cells (29), and pancreatic cells (30). Moreover, there is some evidence from
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clinical studies revealing that metformin improves gut microbiota in obese and type 2 diabetes
mellitus (T2DM) patients; the underlying mechanisms however remain unknown (31).
The metformin-induced increase in AMPK plays an essential role in maintaining energy balance
and controlling glucose metabolism; the cellular AMP/ATP ratio is maintained by increasing
ATP consumption and decreasing ATP production, which is associated with AMPK activation
(24). Recent studies also reported that metformin regulates hepatic gluconeogenesis and
improves hyperglycemia independently of the AMPK pathway (25), suggesting that metformininduced improvement of metabolic disorders can be mediated by other mechanisms. Moreover, it
has been shown that metformin can induce changes in the gut microbiota; however, the
relationship between metformin treatment and the gut microbiota remains unclear (24). In this
study, the composition of the gut microbiota, as well as several metabolic parameters, will be
investigated in a mouse model with high fat diet (HFD)-induced metabolic syndrome receiving
metformin treatment or not. According to recent studies, HFD can affect the intestinal
environment, and thus results in dysbiosis of the microbiome population (32). This causes a
decrease in their distance from the intestinal epithelial cells and thus increased intestinal
permeability and easy passage of lipopolysaccharide (LPS) into the portal blood circulation (33).
The disruption of the intestinal barrier causes gut microbiota-derived endotoxemia and is
believed to contribute to obesity, insulin resistance, and T2DM (34-40). This study further
examines the effects of metformin on reversing obesity and T2DM.

1.4

Intestinal Microbiota may Lead to new therapies for Metabolic Syndrome

In recent years, there has been an enormous interest in the role of microorganisms in the gut,
both bacteria and viruses, in influencing body mass; for instance, a recent study has suggested
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that adenovirus residing in the gut of chickens can cause obesity. It is essential to define the
mechanistic paradigm by which "environmental" (i.e., non-genetic) factors might alter the
microbiota-intestinal interactions, leading to chronic intestinal inflammation, which can manifest
as metabolic syndrome. The epithelium of a healthy gut does not display any signs of
transformation. The change observed in both obese and T2DM patients arises from the
interactions between diet antimicrobials and the often-inadvertent colonization of the gut with
new biota. An inflamed gut shows abnormal structures, which cause thickening of the mucosa
and protrusion of the immune cells, depletion of gamma-aminobutyric acid (GABA) cells,
disruption of the brush border and surface epithelial cells. Only some bacteria can adapt to this
environment. The others, which mainly are responsible for good health in humans, become
scarce or disappear. The excessive use of antibiotics during early childhood, which is already
known to contribute to allergic disorders, inflammatory bowel disease (IBD), and metabolic
problems such as obesity, is another reason for microbiota damage. Moreover, diet can also
cause rapid changes in the microbiota. Thus, a better understanding of the causes of
mismanagement of gut microbiota are of paramount importance.
As previously described, there is a probable correlation between metabolic disorder and
intestinal microbiota. On the other hand, it has been elucidated that the effects of certain
medications on the intestinal microbiota and its bacterial pattern determines their specific
properties. Metformin is believed to be one of these medications. Accordingly, the results of the
present study could be used to develop novel treatments for metabolic syndrome. Furthermore,
this study can set the stage for further research towards the application of fecal transplantation as
a treatment strategy for individuals with conditions such as metabolic syndrome. Using the later
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technique, optimizing the existing treatments would be sufficient to overcome obesity and no
new drugs would be needed.

2 CONSIDERING GUT MICROBIOTA IN TREATMENT OF TYPE 2 DIABETES
MELLITUS
2.1

Abstract

Advances in the understanding of the pathogenesis of type 2 diabetes mellitus has revealed a
role for gut microbiota dysbiosis in driving this disease. This suggests the possibility that
approaches to restore a healthy host-microbiota relationship might be a means of ameliorating
this disorder. Indeed, recent studies indicate that many currently used treatments for type 2
diabetes are reported to impact gut microbiota composition. Such changes in gut microbiota may
mediate and/or reflect the efficacy of these interventions. This article outlines the rationale for
considering the microbiota as a central determent of development of type 2 diabetes and reviews
evidence that amelioration of this disorder in response to therapeutic interventions based on
pharmaceutical reagents and diet involves changes in gut microbiota.
2.2

Introduction: Rationale for considering gut microbiota in diabetes
Type 2 diabetes (T2D) is characterized by loss of glycemic control resulting in

hyperglycemia, especially post-prandially, due to hyporesponsiveness to insulin; i.e. insulin
resistance. The notion that gut microbiota might play a role in this disorder stems largely from
the general appreciation, stemming from work of Jeff Gordon and colleagues, that gut microbiota
contribute broadly to energy balance (41) and the realization of Patrice Cani that microbiota
products such as LPS can drive low-grade inflammation (42), which had long been recognized as
a potential cause of insulin resistance. Re the former, briefly, mice completely lacking
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microbiota (i.e. germfree mice) exhibit reduced energy harvest from ingested food and increased
energy expenditure, associated with increased activation of AMP-activated protein kinase
(AMPK), which plats a central role in energy homeostasis. Such activation of AMPK has been
suggested to protect germfree mice from diet-induced diabetes. While germfree mice can be
considered an extreme state, interpolating their phenotype suggests that differences in microbiota
composition can, more subtly but nonetheless broadly, influence metabolic phenotype and
thereby be a determinant of diabetes and its inter-related metabolic diseases states, namely
obesity and metabolic syndrome. In accord with this notion, obesity in mice and humans is
associated with alterations in microbiota composition, and transfer of microbiota from obese
hosts to germfree mice leads to increased adiposity, relative to germfree mice receiving
microbiotas from lean hosts (43).
The hypothesis that low-grade inflammation drives the insulin resistance that
characterizes T2D type 2 diabetes originated from Hotamisligil and colleagues, who
demonstrated that increases in adipose tissue characteristic of obesity is typically accompanied
by increased expression of pro-inflammatory cytokines, which are produced by adipocytes
themselves and macrophages that are recruited into adipose tissue as obesity develops (44).
While Hotamisligil hypothesized that such pro-inflammatory gene expression resulted from
intracellular stress of adipocytes being overloaded with lipids, Cani found that such
inflammation, and subsequently insulin resistance could result from translocation of
lipopolysaccharide from the gut lumen into portal circulation resulting in activation of proinflammatory gene expression via Toll-like receptor 4 (45). This scenario suggests a variety of
means by which alterations in microbiota composition could impact T2D, including altering
abundance of species that produce LPS and/or other microbial products with strong pro-
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inflammatory potential. It also underscores a key role for epithelial barrier function in restricting
microbial products to the gut lumen. In this context, gut barrier function includes not only
intercellular junctions that directly impede passage of bacterial products but also host systems of
mucus deployment and innate immunity that keep bacteria, themselves, at a safe distance from
the epithelium and help maintain stable microbiota composition. These latter points are shown
by our study of mice that with a discrete defect in innate immunity, namely absence of the
flagellin receptor toll-like receptor 5 (TLR5). TLR5-deficient mice fail to manage their
microbiota, resulting in altered composition, including elevated -Proteobacteria and, moreover,
exhibit microbiota encroachment, which is defined as a decrease in bacterial-epithelial distance
(46, 47). Such alterations result in TLR5-deficient mice developing insulin resistance, which can
be transferred to WT germ free mice via microbiota transplant. Such studies provide a rational
basis for targeting microbiota as a means of preventing and/or treating T2D.
2.3

Alteration of gut microbiota composition in humans with T2D
While much of our understanding of mechanisms whereby microbiota can impact glucose

homeostasis comes from mouse studies, alterations in microbiota composition have also been
observed in a range of human cohorts T2D (48-50). Larsen et. al observed that the Bacteroidetes
to Firmicutes ratio and the ratio of Bacteroides-Prevotella group to C. coccoides-E. rectale
group associated positively with plasma glucose concentration (49). Other differences observed
included decreased abundance of butyrate-producing bacteria, including Clostridiales spp., E.
rectale, Faecalibacterium prausnitzii, Roseburia intestinalis and Roseburia inulinivorans, and
increased abundance of Lactobacillus species. Increased prevalence of Bacteroidetes and
Proteobacteria phyla were also observed. Proteobacteria contain many pathobionts, which can be
envisaged to have a role in inducing low-grade inflammation in diabetic patients through their
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LPS, flagella, and/or other surface components (49). Analysis of microbiota composition in a
cohort of Chinese T2D patients and healthy control subjects observed increased abundance of
opportunistic pathogens including Bacteroides caccae, Clostridium hathewayi, Clostridium
ramosum, Clostridium symbiosum, Eggerthella lenta and E. coli in T2D patients (50). In a
longitudinal cohort on monozygotic Korean twins, it is suggested that decreased Akkermansia
muciniphila could be used as a biomarker for the early diagnosis of type 2 diabetes (51).
Moreover, Acidaminococcus, Aggregatibacter, Anaerostipes, Blautia, Desulfovibrio, Dorea, and
Faecalibacterium have been identified as being associated with type 2 diabetes in a Mendelian
randomization study and these genera should be investigated more in future research (52). While
the wide variety of specific differences can be envisioned to have a variety of functional
consequences, we have observed that TD2 patients exhibit microbiota encroachment (53). Thus,
these human observational studies are in accord with the concept that targeting microbiota is a
logical target to treat insulin resistance and, consequently T2D.
2.4

Interventions that deliberately target microbiota in T2D

An array of studies, some of which are outlined above, indicate that dysregulated or improperly
managed microbiota promotes insulin resistance, leading to the suggestion that broadly
suppressing levels of microbiota might be a means of ameliorating this disorder. While,
relatively short-term studies in mice support this concept, it is unlikely to prove a therapeutic
option to manage this chronic disease in humans due to the general negative impacts of
antibiotics on gut health, especially relating to risk of serious infection by antibiotic resistant
bacteria. Moreover, numerous studies have associated frequent use of antibiotics with T2D, thus
further supporting the role of a stable microbiota in preventing T2D but arguing against the
notion that broad-based ablation of microbiota can be a practical approach to treat T2D in
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humans. Rather, direct deliberate attempts to influence microbiota composition to promote
insulin sensitivity and thus ameliorate T2D have utilized fecal microbiota transplant (FMT),
probiotics or prebiotic. The latter will be discussed below under dietary fiber, since such studies
were often initiated prior to appreciation of the role of microbiota. Here, we discuss FMT and
use of specific probiotics.
The logic of FMT is relatively straight forward, namely to replace a dysbiotic microbiota
with a healthy one, which will have the needed diversity to stably persist in its new host. Proof of
concept generally comes from mouse studies wherein transplanted communities persist in their
new hosts for extended periods and the highly effective use of FMT to prevent recurrence of C.
difficile infection. Use of FMT to ameliorate insulin resistance in humans is largely the work of
Nieuwdorp and colleagues whom have performed well-controlled randomized clinical trials
studying this approach. Such trials have shown that, following colonoscopy in which the
preparation of the colon removes a considerable portion of the total microbial mass in the
intestine, FMT from healthy subjects, or persons with good glycemic control as result of bariatric
surgery, can improve insulin sensitivity relative to FMT with one’s own feces (i.e. placebo
control) (54, 55). However, the beneficial impacts are transient as is the engraftment of the
donor microbiota. Moreover, a variety of poorly understand factors in recipient’s microbiota
influence both engraftment and any beneficial metabolic impacts (56). The transient nature of
these effects may reflect that, unlike germfree mice, the microbiota of a host with an established
microbiota is more difficult to permanently replace and/or that whatever causes had led to an
unhealthy microbiota in the first place, for an example, an unhealthy diet, have not changed and
will result in failure to maintain the engraft microbiota. In any case, collectively, results from
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FMT studies support the notion that changing microbiota can positively impact diabetes but
underscores that doing so in a lasting manner is not yet be easily achieved.
2.5

Probiotics in diabetes

One potential approach to attaining a healthy microbiota is to directly administer beneficial
bacteria; i.e. probiotics, which the International Scientific Association for Probiotics and
Prebiotics defines as "live microorganisms which when administered in adequate amounts confer
a health benefit on the host” (49). Experimental studies and clinical trials support the hypothesis
that the modulation of the intestinal microbiota by probiotics could be effective in diabetes
management (50) in which the most widely studied probiotics with respect to diabetes are
Bifidobacterium and Lactobacillus strains. Specific strains of L. rhamnosus, L. acidophilus, L.
gasseri and L. casei have been demonstrated to exert anti-diabetic effects (51-55). Moreover,
several strains of L. plantarum species have been reported to improve the glycemic control in
obese and diabetic patients by their carbohydrate-utilizing genes (56, 57). Bifidobacterium
animalis, B. breve and B. longum could also be helpful in improvement of glucose intolerance
(58, 10, 19). While results individual studies are variable, a recent meta-analysis has shown that
these probiotics improve glycemic control and significantly decrease the risk of gestational
diabetes mellitus in pregnant women (60). Underlying mechanisms by which probiotics might
have impacted host metabolism have not been well defined but may include favorable changes of
the composition and/or activity of the microbiota, inhibition of α-glucosidase activity, production
of anti-microbial lactic acid, improvement of intestinal barrier function, immune modulation,
short-chain fatty acid production, and regulation of bile acid metabolism (58,50,61). Other
candidate probiotics include gut bacteria including Akkermansia muciniphila and
Faecalibacterium prausnitzii, which are negatively associated with overweight and
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hyperglycemia, may be potential candidates for next generation probiotics; further studies are
needed in this field (62). A recent placebo-controlled trial supported this concept in that direct
administration of Akkermansia muciniphilia improved glycemic control in persons with
metabolic syndrome although, unexpectedly, the impact of heat-killed Akkermansia appeared
more significant than that of the live organism highlighting that further development is needed
before deploying this strategy on a large scale.
2.6

T2D pharmaceutical agents that impact microbiota
While deliberate targeting of the microbiota to ameliorate T2D is clearly in early stages

of development, it is increasingly being appreciated that several drugs that have long been used
to treat T2D result in impacts on gut microbiota in a manner that might contribute to their
efficacy
2.7

Metformin

Metformin (dimethyldiguanide), discovered in 1922 based on study of the plant Galega
officinalis (Goat’s Rue) to lower blood glucose, is a very common treatment for T2D, especially
T2D associated with obesity. Yet, its mechanism of action remains unclear but may include
inhibition of mitochondrial function via respiratory chain complex I or glycerophosphate
dehydrogenase, activation of 5' AMP-activated protein kinase (AMPK), and amelioration of
glucagon-induced cAMP. Moreover, there is evidence to suggest a role for gut microbiota in
mediating metformin’s ability to improve glycemic control. In contrast to oral metformin,
intravenous administration of metformin lacks does not control hyperglycemia thus suggesting
the intestine as an important site of metformin action (57). Furthermore, in both mice and
humans, metformin alters microbiota composition to make it more resembling of microbiotas of
healthy hosts (58-60). Some of these changes were observed amidst healthy persons who don’t
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exhibit changes in glycemic control in response to this agent thus suggesting the changes in the
microbiota result from metformin itself rather than simply reflect improved glycemic control.
Yet specific associations have been variable amongst different studies and different states of
health in part reflecting the difficulty of dissociating impacts on microbiota due to drugs and/or
disease. Overall, in healthy subjects, metformin impacted relative abundance of several phyla
including a reduced abundance of Intestinibacter spp. and Clostridium spp., as well as an
increased abundance of Escherichia/Shigella spp. and Bilophila wadsworthia. Some of these
changes appear reminiscent of changes associated with disease and thus irrespective of potential
impacts on glycemic control such change may contribute to gastrointestinal distress, which is the
leading cause of metformin intolerance. Indeed, prevalent gastrointestinal side-effects after
metformin intake including diarrhea, nausea, vomiting, and bloating have been attributed to
increased abundance of Escherichia (61).
Regarding how such changes might impact glycemic control, metagenomic analysis of
microbiota suggests a range of functional categories of microbial genes that are impacted,
including those related to oxidative stress and metal transport. Additionally, metformin-induced
changes in microbiota are proposed to impact production of butyrate and propionate activating
intestinal gluconeogenesis (62, 63). Stimulated gluconeogenesis in gut has beneficial effects on
hepatic glucose production and appetite suppression, contributing to weight reduction and
glycemic control (64). On the other hand, expression of microbial genes involved in the
degradation of glycine and tryptophan was higher in the untreated diabetic patients compared to
metformin-treated patients. Since glycine has been reported to improved insulin sensitivity, this
pathway could be nominated as another underlying mechanism (65).

17

One approach that suggests the overall impact of metformin-induced changes in
microbiota are beneficial is that transfer of microbiota from metformin-treated mice was
observed to improve metabolic parameters in aged mice suggesting changes in microbiota play a
functional role in its beneficial metabolic effects (59). However, this approach does not address
the extent to which changes in microbiota are necessary for its impact. We recently investigated
this question in mice. We found that the ability of metformin to beneficially impact metabolic
syndrome in mice was not impacted by ablation of gut microbiota achieved by use of antibiotics
or germfree mice. Rather, while microbiota ablation itself suppressed diet-induced dysglycemia,
other features of metabolic syndrome including obesity, hepatic steatosis, and low-grade
inflammation were similarly suppressed by metformin in the presence or absence of gut
microbiota. While this approach did not directly informative re the role of microbiota in
metformin-induced improvement in glycemic control, it suggests a potential role for metformin’s
anti-inflammatory activity, irrespective of gut microbiota, in driving some of this drug’s
beneficial impacts.
2.8

Other drugs proven to benefit T2D
Acarbose, α-glucosidase inhibitor, lowers postprandial blood glucose concentration via

inhibiting conversion of oligosaccharides into mono- and di-saccharides and delaying intestinal
glucose absorption. However, acarbose has also been recently appreciated to impact microbiota
composition. For example, assessing gut microbiota alteration after acarbose treatment in type 2
diabetic patients showed increased abundance of Bifidobacterium longum and decreased
concentration of lipopolysaccharides (66). In another clinical trial in patients with prediabetes,
Butyricicoccus, Phascolarctobacterium, and Ruminococcus decreased while Lactobacillus,
Faecalibacterium and Dialister increased after acarbose intake (67). These compositional shifts
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of gut microbiota after acarbose intake suggested microbial mediation of the therapeutic effects
of acarbose in part. The extent to which these changes may contrinute to acarbose’s impacts on
glycemic control are not known.
Stimulation of glucagon-like peptide-1 release has been declared as a potential mediating
mechanism for the effects of SCFAs on glucose homeostasis. Glucagon-like peptide-1 as a gut
hormone is involved in appetite control and gastric emptying. GLP-1 receptor agonists like
liraglutide slow gastric emptying, stimulate satiety, enhance insulin secretion, and suppress
glucagon (68). In animal models of obesity, liraglutide induced a reduction of Proteobacteria and
an increase of Akkermansia muciniphila in gut microbiota (69). Another study on diabetic male
rats reported enhancement of SCFA-producing bacteria, including Bacteroides,
Lachnospiraceae, and Bifidobacterium after injection of liraglutide (70). Liraglutide
substantially altered the overall composition of the gut microbiota, consistent with its weightlowering effect (71). Genera including Allobaculum, Turicibacter , Anaerostipes, Blautia,
Lactobacillus, Butyricimonas and Desulfovibrio enhanced and the orders including
Clostridiales and Bacteroidales diminished after intervention, consistent with changes reported
in gut microbial composition after body weight control (71). Further investigations are needed to
elucidate the role pf microbial mediation in the therapeutic effects of GLP-1 receptor agonists.
Another agent used in treatment of T2D is Pioglitazone, which is a member of of
the thiazolidinedione class with hypoglycemic effects thought to result from stimulating activity
of the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ). Such
stimulation results in reducing insulin resistance and decreasing liver gluconeogenesis (72). In
animal models of T2D, Pioglitazone decreases diversity of gut microbiota and shift beta diversity
in C57BL/6J mice (73). This suggests a possible involvement of the microbiota although human
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studies re hos this drug impacts microbiota in T2D and other diseases states have not been
reported
It has been found that Sitagliptin and Vildagliptin, DPP-4 inhibitors, altered gut microbial
composition in diabetic rats (74, 75). These drugs reduced the diversity of microbiota, increased
the abundances of short-chain fatty acids-producing bacteria including Blautia, Roseburia,
Clostridium, Baceroides and Erysipelotrichaeae in gut microbiota and corrected the
Bacteroidetes/Firmicutes ratio (74, 75). Therefore, it has been suggested that these drugs may
have beneficial effects on blood glucose partly through maintaining the gut barrier integrity and
correcting the dysbiosis of intestinal microbiota in diabetes although human studies are needed in
this regard.
2.9

Herbal agents used to treat T2D and gut microbiota
Many societies have long treated T2D with a variety of plant-based products and extracts.

In some cases, active ingredient(s) have been isolated with results suggesting a potential rolefor
microbiota. Additionally, a range of herbal-derived products including berberine, resveratrol,
alliin, capsaicin, betacyanins, and cranberry proanthocyanidins have bioactions and antidiabetic
effects potentially mediated by modulation of gut microbiota (76-83). Galactomannan, pectin,
capsaicin, and red pitaya betacyanins altered the proportion of Firmicutes to Bacteroidetes (7880). Increased fecal butyrate concentration and Roseburia abundance and decreased Bacteroides
and Parabacteroides abundances have been reported after intervention by capsaicin in obese
diabetic ob/ob mice (80). Alliin from garlic caused decrease in Lachnospiraceae abundance and
increase in Ruminococcaceae abundance which enhanced glucose homeostasis and insulin
sensitivity, but has no effect on adiposity (81). Berberine decreased the relative abundance of
branched-chain amino acids-producing bacteria, including Streptococcus and Prevotella whereas
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increased the relative abundance of short-chain fatty acids-producing bacteria, including Blautia
and Allobaculum (82, 84). It has been shown that berberine exerts comparable effects to
metformin in altering the microbial diversity and overall structure of the gut microbiota in highfat diet-induced obese rats (85).
For some herbal extracts, active ingredients are not well defined, nor is their efficacy, nor
mechanism of action, although there is increasing effort being applied to fill these gaps of
knowledge. Herbs common in traditional Chinese medicine for glycemic control of diabetic
patients includes Folium Mori, Dendrobium candidum, Rhizoma Dioscoreae, Coptis chinensis,
Fructus MoriL (86, 87). For example, a multicenter randomized clinical trial on type 2 diabetic
patients revealed that both metformin and a traditional Chinese herbal formula significantly
alleviated hyperglycemia and dyslipidemia. Such effects correlated with impacts on gut
microbiota wherein the herbal mixture had larger effect on this. Changes in microbiota induced
by these herbal formulations included enrichment of Blautia and Faecalibacterium spp., which
are thought to be benefici herbal preparations impact gut microbiota composition, suggesting it
as a possible contributor to their effects. A range of individual herbal extracts that have been
used to treat T2D impact microbiota. Alpinia oxyphylla Miq. extract was found to
improve glycemic control and renal function in diabetic mice in a manner that associated with
increased abundance of Akkermansia and increasing the ratio of Bacteroidetes-to-Firmicutes (88)
Increased Bacteroidetes to Firmicutes has also shown after intervention with Qijian mixture
(Astragalus membranaceus, Ramulus euonymi, Coptis chinensis and Pueraria lobata) and
extract of Dendrobium loddigesii (49, 50). Increased abundance of Akkermansia was also
associated with glucose-lowering properties of polyphenol-rich extracts of cranberry. Waterethanol extract of green macroalgae Enteromorpha prolifera and Oil tea (green tea and ginger)
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enriched Lachnospiraceae has been reported after intake of in animal studies (91, 92), and was
suggested to underlie its beneficial impact on glycemic control. Extracts of cinnamon bark and
grape pomace induced a decrease in Peptococcus, Desulfovibrio, Lactococcus abundances and
an increase in Allobaculum and Roseburia abundances (93), which associated with decreased fat
mass, reduced adipose inflammation, and improved glucose tolerance (93). The notion that
beneficial impacts of herbal extracts are mediated by reduced inflammation is supported by a
study that found Dendrobium loddigesii and Houttuynia cordata, which are traditional Chinese
treatment for T2D results decreased abundance of Gram negative bacteria including Escherichia
coli and Bacteriodetes fragilis that was suggested to improve T2D by reducing exposure to LPS
absorption and subsequently inflammatory (90, 94). Moreover, Dendrobium loddigesii was
reported to improve the gut barrier integrity, which can also reduce metabolic endotexemia and
insulin resistance (83, 90). In summary, changes in gut microbiota in response to herbal extracts
include increasing microbial diversity, reducing the Firmicutes/Bacteroidetes ratio, increasing
the abundances of anti-inflammatory bacteria such as Biﬁdobacterium, Lactobacillus,
Akkermansia, and Faecalibacterium, and decreasing the pathogenic bacteria such as Escherichia
coli and Enterococcus, which might alleviate low-grade inflammation subsequently improving
glycemic control.
2.10 Microbiota-metabolizable carbohydrates (fermentable fiber)
In addition to specialized, plants and extracts, one major type of macronutrient that has
long been recognized as important for metabolic health in general, and thus potentially
promoting good glycemic control is dietary fiber. While mechanisms by which fiber might
promote metabolic health are complex, it has recently been appreciated that such beneficial
impacts are mediated, at least in part by gut microbiota (95). Briefly, complex carbohydrates that
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reach the colon that can be fermented by gut bacteria are the major fuel source of the microbiota
and has such will have a major impact on total levels of bacteria, composition and its functional
activity. Re the former, in mice, lack of fiber decimates microbiota density, which slows
enterocyte proliferation, deteriorates mucus, and alters microbiota composition, which together
result in microbiota encroachment that promotes low-grade inflammation and insulin resistance
(95, 96). Hence, enriching a “western-style” low-fiber high-fat diet with fermentable but not
insoluble fiber restores gut health and prevents these consequences. The notion that changes in
microbiota are pivotal to such impacts of fiber on glycemic control include lack of effects of
such fiber in germfree conditions and that addition of some of the specific bacteria enriched by
fiber, namely bifidobacterial could provide beneficial metabolic impacts. A range of other
fermentable fibers, including pectin and glucomannan, and resistant corn starches, which can be
considered functionally fibers, also impact microbiota and improve glycemic control. The
caveats of such studies include that it is difficult to disentangle impacts on glycemic control from
other interrelated parameters of metabolic syndrome and that they are largely restricted to mice.
In contrast, study of one highly fermentable fiber, inulin, has revealed this fiber can increase
levels of Akkermansia muciniphilia in both mice and humans (97). Levels of this microbes are
reduced in T2D and direct administration of this microbe to mice improves glycemic control and
has shown promise in a recent human trial. In terms of mechanisms, by far the most studied
aspects of how nourishing microbiota might improve glycemic control involves the major
product of fiber fermentation, short-chain fatty acids (SCFA). SCFA have a variety of direct
metabolic benefits that can improve insulin-resistance irrespective and have a variety of antiinflammatory actions that can be expected to indirectly. However, ability of fermentable fiber,
while fully microbiota-dependent, does not absolutely require SCFA per se in that blocking
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fermentation only moderately reduced impact of such fibers. Rather, nourishing microbiota with
fermentable fiber inulin led to host IL-22 production that was necessary to improve glycemic
control and restore gut health, which is impaired by western-style diet. Yet, another means by
which inulin improves glycemic control involves its enrichment of Akkermansia muciniphilia,
which restores mucus robustness resulting in protection against low-grade inflammation (98).
While the notion that a bacteria that feeds on mucus results in more robust mucus is somewhat
counter-intuitive, it can be viewed as analogous to the notion that cutting a lawn of grass
encourages dense growth. Thus, to some extent microbiota mediated approaches to treating
preventing T2D can be viewed in terms of ameliorating inflammation.

2.11 Conclusions & Perspective
TD2 is currently, and seems likely to remain for some time, one of humanities major public
health problems. As such humanity needs new approaches to treat and prevent this disorder.
While most treatments currently in use, especially pharmaceutical agents with proven effects,
have generally focused on agents designed to directly impacts signaling pathways that directly
regulate glucose, or work by unknown mechanisms, better understanding of root causes of T2D
suggest targeting the gut microbiota might be a logical approach to treating this disorder. As
reviewed herein, studies, especially those in animal models, support this notion. Moreover,
investigation of currently used pharmaceutical reagents suggest their beneficial effects may be,
in part, mediated by impacts on gut microbiota. Given that dysglycemia itself impacts
microbiota, disentangling cause and effect is a major confounder this area of research. Yet, we
submit that, even if such changes in microbiota are, initially, a consequence of improved
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glycemic control, they may still be part of maintaining good glycemic control. Thus, examining
how, in humans. current and future treatments of T2D is important to understanding impacts of
these agents on health, regardless of whether these agents directly impact microbiota. Similar
logic applies to diet-type approaches to ameliorate T2D. Indeed, approaches like caloric
restriction to prevent T2D have long preceded appreciation of the microbiota but recent studies
that this approach impacts microbiota suggest it as a possible mediator of its prevention of this
disorder. In this regard, we suggest that further study and consideration of microbiota, in
humans, in response to both pharmaceutical and dietary interventions should pave the way for
better approaches to treat and prevent T2D.

3 AMELIORATION OF METABOLIC SYNDROME BY METFORMIN
ASSOCIATES WITH REDUCED INDICES OF LOW-GRADE INFLAMMATION
INDEPENDENTLY OF THE GUT MICROBIOTA
3.1

Abstract

Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia,
obesity and liver dysfunction, thus making it a widely used frontline treatment for early-stage
type 2 diabetes, which is associated with these disorders. Several mechanisms of action for
metformin have been proposed, including that it acts as anti-inflammatory agent, possibly as a
result of its impact on intestinal microbiota. In accord with this possibility, we observed herein
that, in mice with diet-induced metabolic syndrome, metformin is impacting the gut microbiota
by preventing its encroachment upon the host, a feature of metabolic syndrome in mice and
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humans. However, the ability of metformin to beneficially impact metabolic syndrome in mice
was not markedly altered by reduction or elimination of gut microbiota achieved by use of
antibiotics or germfree mice. Rather, while reducing or eliminating microbiota by itself
suppressed diet-induced dysglycemia, other features of metabolic syndrome including obesity,
hepatic steatosis, and low-grade inflammation remained suppressed by metformin in the presence
or absence of gut microbiota. These results support a role for metformin’s anti-inflammatory
activity, irrespective of gut microbiota, in driving some of this drug’s beneficial impacts on
metabolic syndrome.
3.2

Introduction
The marked worldwide increased prevalence of type 2 diabetes (T2D) is thought to be

driven, in large part, by increased prevalence of obesity (108). Obesity promotes an array of
metabolic disorders collectively referred to as metabolic syndrome whose features include
hypertension, hyperlipidemia, and, most importantly, insulin resistance, which is the central and
defining cause of T2D. Metformin (dimethyldiguanide), discovered in 1922 via investigating the
ability of the herb Galega officinalis (Goat’s Rue) to lower blood glucose, is widely used as a
frontline treatment for T2D, especially T2D associated with obesity, in part due its ability to
beneficially impact multiple parameters of metabolic syndrome including obesity and liver
dysfunction (99). Several mechanisms by which metformin alleviates metabolic syndrome have
been proposed, including inhibition of mitochondrial function via respiratory chain complex I or
glycerophosphate dehydrogenase, activation of 5' AMP-activated protein kinase (AMPK), and
amelioration of glucagon-induced cAMP. Moreover, several studies suggest a central role for gut
microbiota in mediating metformin’s amelioration of metabolic syndrome.
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The notion that metformin’s action is mediated by impacts on gut microbiota is supported
by reports that, in both mice and humans, metformin alters microbiota composition to make it
more resembling of microbiotas of healthy hosts (111). Furthermore, transfer of microbiota from
metformin-treated mice was observed to improve metabolic parameters in aged mice suggesting
changes in microbiota play a functional role in its beneficial metabolic effects (124). A range of
potential means by which select alterations in microbiota by metformin might ameliorate
metabolic syndrome have been proposed including impacting sensing of glucose in the small
intestine (102), direct alteration of metabolism of ingested food so as to increase bacterial
fermentation (109), and alteration of bile acids (113).
More generally, we hypothesize that metformin’s restoration of a healthy microbiota
composition might reduce the microbiota’s capacity to induce host inflammation, which occurs
in metabolic syndrome and is known to promote this disorder (104). Our observations that, in
both mice and humans, dysglycemia is associated with reduced bacterial-epithelial distance, a
state referred to as “microbiota encroachment”, suggests that alterations in microbiota
composition and/or gene expression can influence microbiota localization, which may influence
low-grade inflammation and consequently metabolic syndrome (106,107). Hence, we
hypothesized that metformin’s impact on microbiota composition might reduce microbiota
encroachment, consequently ameliorating metabolic syndrome. In accord with this hypothesis,
together with previous observations reporting that metformin results in beneficial impacts on gut
microbiota (124,127), we observed herein that metformin-induced changes in microbiota
composition that associated with alleviation of microbiota encroachment, low-grade
inflammation and metabolic syndrome. However, in contrast to our hypothesis, we failed to
demonstrate that the ability of metformin to alleviate metabolic syndrome required the presence
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of a microbiota. In part, this observation may reflect that one of the central parameters of the
metabolic syndrome that is treated by metformin, namely dysglycemia, is itself ameliorated by
reducing or eliminating microbiota thus obscuring metformin’s potential to improve glycemic
control (103). Nonetheless, our results argue that metformin may ameliorate metabolic syndrome
by reducing adiposity and/or low-grade inflammation per se rather than acting directly on gut
microbiota.
3.3
3.3.1

Experimental Procedures
Mice and high-fat diet administration

Male, 4-6 week old C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, ME)
and maintained at Georgia State University, Atlanta, Georgia, USA under institutionally
approved protocols (IACUC # A18006), housed 5 mice per cage with ALPHA-dri bedding
(Shepherd Specialty Papers) and nestlets (Ancare) and fed ad libitum. Mice were fed standard
grain-based chow (GBC), Purina/Lab Diet 5001, which is comprised of relatively unrefined
ingredients and given 2 weeks to allow for microbiota stabilization. Where indicated, mice were
then administered a diet composed of 60% kcal from fat (Research Diet, D12492) for 8-12
weeks. For germfree experiments, we utilized an irradiated version of this diet (10-20 KGy) that
achieves sterilization.
3.3.2

Metformin administration
Metformin, 1,1-dimethyl biguanide hydrochloride (Sigma-Aldrich) was administered via

intraperitoneal (IP) injection or orally concurrent with HFD exposure. For IP route, 100 l of
saline (NS, vehicle control) or NS containing an amount of metformin that resulted in 300 mg
metformin/kg weight, which equates to a 20g mouse receiving 6 mg per day. For oral
administration, metformin was added to drinking water at a concentration of 3 or 10 mg/ml or
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which was calculated to result in ingestion of 9 or 30 mg per day based on 3 ml water
consumption per day. These doses were selected as being typical from reading several papers
(101, 125,126). While higher than used in humans, they are approximately similar to that used in
other studies in mice.

3.3.3

Microbiota reduction
Antibiotics: Mice were administered drinking water containing ampicillin (1.0 g/l) and

neomycin (0.5 g/l) upon HFD feeding and continued until mice were euthanized.
Germfree mice: Germ-free wild-type C57BL/6 male mice were purchased from Taconic Inc. and
maintained in Isocages (Techniplast USA, West Chester, PA), using procedures which we’ve
shown maintain a germfree state (31). To assure sterility of metformin, after dilution it was
filtered through Nalgene™ Rapid-Flow™ Sterile Disposable Filter Units with PES Membrane of
0.2 µm units, protect against bacterial contamination. Similarly-filtered water was used for the
control group. GF mice were fed autoclaved chow or -irradiation (10-20KGy) HFD. To verify
that HFD was truly sterilized by the irradiation, we measured levels of bacterial DNA in feces
before and after feeding of this diet as previously described (129). After 8 weeks of metformin
treatment, mice were fasted overnight, removed from isocages and immediately euthanized.
Lastly, we note that the germfree experiment was done in parallel with another study focused on
comparing chow-fed and HFD-fed mice and thus those mice served as control groups for
metformin-treated mice (Tran et. Al. CMGH, manuscript in revision).
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3.3.4

Fasting Blood Glucose Measurement

Mice were placed in clean cage, fasted for 5 h or overnight as indicated, and blood glucose was
measured by Nova Max Glucose Meter and expressed in mg/dL.

3.3.5

Magnetic resonance imaging (MRI)

Bruker MiniSpec MRI Body Composition Measurement was used for MRI fat % using open
source MiniSpec software. Mice were weighed, placed into restrainer, inserted into assay tube
and data collected for 2 min. Data is expressed as % fat.

3.3.6

Bacteria localization by FISH Staining

Microbiota localization was performed as previously described (Chassaing et al., 2015) and (Jun
Zou et al, 2017)

3.3.7

Microbiota analysis by 16S rRNA gene sequencing

Microbiota composition was performed as previously described (Chassaing et al., 2015).
Unprocessed sequencing data are deposited in the European Nucleotide Archive under accession
number ERP117168.

3.3.8

RNA Isolation and QRT-PCR

Total RNA was extracted from transverse colonic tissues, liver and adiposity using TRIzol
(Invitrogen, Carlsbad, California) according to the manufacturer’s protocol. Quantitative RT–
PCR was performed using the iScript One-Step RT–PCR Kit with SYBR Green (Bio-Rad,
Hercules, California) in a CFX96 apparatus (Bio-Rad, Hercules, California) with the primers
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listed are listed below in transcript levels were quantified by normalization of each amplicon to
housekeeping gene 36B4.
(36B4: 5’ TCCAGGCTTTGGGCATCA-3’ and 5’CTTTATTCAGCTGCACATCACTCAGA-3’
from Invitrogen)
(CXCL1: 5’ TTGTGCGAAAAGAAGTGCAG-3’ and 5’TACAAACACAGCCTCCCACA-3’
from Invitrogen)
(IL-6: 5’ GTGGCTAAGGACCAAGACCA-3’ and 5’GGTTTGCCGAGTAGACCTCA-3’ from
Invitrogen)
(TNF-α: 5’ CGAGTGACAAGCCTGTAGCC-3’ and 5’CATGCCGTTGGCCAGGA-3’from
Invitrogen)
3.3.9

Quantitation of microbiota by qPCR

Total DNA was isolated via QIAamp DNA Stool Mini Kit (Qiagen). DNA was then subjected to
quantitative PCR using QuantiFast SYBR Green PCR kit (Biorad) with universal 16S rRNA
primers (515 F GTGCCAGCMGCCGCGGTAA) and (806 R GGACTACHVGGGTWTCTAA)
to quantitate total bacteria. Results are expressed as bacteria number per mg of stool, using a
standard curve generated from dilutions of a purified culture of E. coli. Proteobacteria analysis
used the following primers purchased from Invitrogen: Gamma 877F:
GCTAACGCATTAAGTRYCCCG and Gamma 1066R GCCATGCRGCAAATGTCT, Beta
979F: AACGCGAAAAACCTTACCTACC and TGCCCTTTCGTAGCAACTAGTG, Epsilon
940F: TAGGCTTGACATTGATAGAATC and CTTACGAAGGCAGTCTCCTTA from
Invitrogen)
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3.3.10 Western blot
Due to the high lipid content of livers from HFD-fed mice, Sample were extracted using a high
volume of lysis buffer (500 l per 100 mg) this permitting easy separation of lipid and
proteinaceous fractions thus allowing protein quantification and SDS-PAGE immunoblotting to
proceed using anti-Phospho-AMPK monoclonal and anti-AMPKa rabbit polyclonal antibodies
from Cell Signaling at 1:200 dilutions.
3.3.11 Histology
Mouse colon, adipose tissue, and liver were ﬁxed in 10% buffered formalin at room temperature
before embedding in parafﬁn. Tissues were sectioned at 5 mm thickness and stained with
hematoxylin and eosin (H&E). The picture capture by Image by software OLYMPUS VS-ASW
virtual slide system from H&E. Steatosis was graded 1-5 wherein a score of 1 was assigned for
no discernable steatosis (relative to chow-fed mice), and scores of 2-5, on a 0.5 interval used to
grade modest to severe steatosis.

3.3.12 ELISAs
Serum from overnight-fasted mice was assayed for MCP-1 via a Duoset ELISA purchased from
R&D Systems. Serum insulin was measured with an ELISA kit (Cat: EZRMI-13K) purchased
from Millipore, inc. Fecal Lipocalin-2 was measured as previously described.

3.3.13 Quantification and Statistical Analysis
Data were expressed as mean ± SEM. Statistical significance was analyzed by unpaired
Student’s t test (GraphPad Prism 7). Differences between experimental groups were considered
significant at P < 0.05
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3.4
3.4.1

Results
Metformin’s amelioration of diet-induced metabolic syndrome is associated with
beneficial impacts on gut microbiota
While, in humans, Metformin is generally administered orally, most studies of this drug

in mice have relied upon systemic administration, typically intraperitoneal (IP) administration, in
which relatively moderate doses of this drug are able to ameliorate various aspects of metabolic
syndrome (115,116). Hence, our initial approach was to examine the extent to which IP
administration of metformin ameliorated metabolic syndrome and microbiota composition in
mice fed an obesogenic western-style high-fat diet (HFD), which is high in saturated fats and low
in fiber. Mice (C57BL/6 males) were maintained on standard grain-based rodent chow or, at 6
weeks of age, administered HFD ad libitum and 2 weeks later, given daily injections of vehicle
(normal saline, NS) or metformin. Such metformin treatment ameliorated various other aspects
of metabolic syndrome including obesity, as assessed by body weight and adiposity (Fig 3.6.1AC and 3.7.1), dysglycemia (Fig 3.6.1 D), and hepatic steatosis (Fig 3.6.1G&H). Moreover, in
accord with the general notion that metabolic syndrome is characterized low-grade inflammation,
which might be impacted by metformin (directly and/or via metformin’s impacts on gut
microbiota), we observed that metformin ameliorated indices of HFD-induced low-grade
inflammation, including colon shortening (Fig 3.6.1E) and increases in levels of serum
macrophage chemotactic protein-1 (MCP-1), (Fig 3.6.1F), which associates with diet-induced
obesity (121,129). Together, these results indicate that, in accord with previous studies, IP
administration of metformin ameliorated HFD-induced low-grade inflammation and metabolic
syndrome.
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Next, we considered the extent to which metformin impacted gut microbiota
composition, envisaging that metformin administered IP might reach the intestinal lumen via bile
trafficked by enterohepatic circulation and/or that metformin might indirectly impact the
microbiota. Feces were collected from HFD-fed mice immediately prior to and 10 weeks
following IP administration of vehicle or metformin. We utilized 2 cages of mice (5 per cage) in
order to reduce chances of observing differences that primarily reflected the tendency of mice to
have microbiomes that resemble that of their cagemates, due to their coprophagic habits. Fecal
microbiota composition was assessed via sequencing of 16S ribosomal RNA genes. Overall,
untargeted assessment of microbiota composition was assessed by plotting of principal
coordinates of Uni-Frac values. Prior to treatment, overall microbiota composition did not differ
significantly between mice that had been assigned to the metformin and vehicle groups (Fig
3.6.2A, week 2). In contrast, at 10 weeks following metformin treatment, there was a marked
distinction in overall microbiota composition between metformin and vehicle-treated mice (Fig
3.6.2A, week 12). The extent of this change was such that it could be visualized even amidst the
large change in microbiota composition that resulted from prolonged exposure to HFD. Such
changes in microbiota composition reflected enrichment and depletion of a variety of taxa (Figs
3.6.2 and 3.7.2), without an impact on species richness (i.e. -diversity) (Fig 3.6.2C). One
general consequence of alterations in the host-microbiota relationship in diabetic patients and
mice with metabolic syndrome is encroachment of gut microbiota into the inner mucus layer,
which might result in such bacteria promoting low-grade inflammation (107). Moreover,
metformin increases goblet cells, which increases mucus thickness (120). Hence, we measured
by confocal microscopy the extent to which metformin impacted bacterial-epithelial distance.
We observed that metformin treatment resulted in greater bacterial-epithelial distance (Fig 3.6.2
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D&E). Together, these results indicate that metformin treatment of HFD-fed mice resulted in
changes in microbiota composition and localization that may reduce low-grade inflammation and
are thus in accord with previous studies that suggest that the beneficial actions of this drug may
be mediated, in part, by gut microbiota.

3.4.2

Metformin ameliorates metabolic syndrome in the absence of a microbiota
The above-described and previously reported (124,127) impacts of metformin on gut

microbiota can be envisaged to contribute to, and/or reflect, metformin’s ability to ameliorate
metabolic syndrome. Hence, we next examined if reducing levels of gut microbiota via antibiotic
treatment would impact ability of this drug to ameliorate HFD-induced metabolic syndrome.
Metformin or vehicle was administered to HFD-fed mice, as described above or under conditions
wherein vehicle- and metformin-treated mice were subjected to a mixture of antibiotics, namely
ampicillin and neomycin, administered via their drinking water. As expected antibiotics quickly
resulted in a more than 3-log reduction in the total amount of bacteria per mg of feces that was
maintained, irrespective of metformin treatment, throughout the course of the 12-week period of
administration utilized (Fig 3.6.3A). While the reduction of metformin on HFD-induced weight
gain was not seen under conditions of antibiotic administration (Fig 3.6.3B), this may have
reflected that the weight gain itself was reduced by antibiotics. In any case, the extent to which
metformin suppressed adiposity, as measure by MRI (Fig 3.6.3C) or post-euthanasia measured
fat pad mass (Fig 3.6.3D) was not markedly impacted by antibiotic treatment, which itself had
only a minor impact on increased adiposity. Nor did the antibiotics prevent metformin from
ameliorating hepatic steatosis (Fig 3.6.3E and S3.7.3). Moreover, while antibiotics moderately
reduced fasting blood glucose in HFD-fed mice, particularly at later time points following HFD
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exposure, metformin still lowered this parameter particularly at these later time points (Fig
3.6.3F). Nor did antibiotic administration prevent metformin from ameliorating indices of lowgrade inflammation that are known to result from exposure to HFD. Specifically, metformin
reduced serum MCP-1 (Fig 3.6.3G) and adipose levels of MCP-1 and TNF mRNA (Fig
3.6.3H&I), irrespective of antibiotic treatment. Additionally, while the extent to which
metformin protected against colon shortening, which is an indicator of inflammation, was
variable, it was significant under conditions of antibiotics (Fig 3.6.3J). Lastly, use of PCoA
analysis to holistically considering all of these metabolic and inflammatory parameters (Fig
3.6.3K) indicated that metformin-treated mice had similar overall metaboinflammatory
phenotypes irrespective of antibiotic treatment. Thus, overall, use of antibiotics to markedly
reduce gut bacterial loads did not support our original hypothesis that the ability of metformin to
ameliorate metabolic syndrome was mediated by its actions on gut microbiota.
One caveat to the above-described studies is that administering metformin via the IP
route may have reduced interaction of this drug with the intestinal mucosa and luminal
microbiota. One the one hand, that IP metformin altered gut microbiota and that metformin
administered IP might reach the intestinal lumen via bile trafficked by enterohepatic circulation
argues against the importance of this caveat. On the other hand, given that several studies, albeit
largely-association based, have implicated an important role for microbiota in mediating
metformin’s impact, we sought to develop a means of orally delivering metformin that would
ameliorate HFD-induced metabolic syndrome. Hence, we sought to develop an oral dosing
regimen in which metformin markedly and reliably ameliorated HFD-induced metabolic
syndrome. First, based on published work, we administered metformin in drinking water to
deliver a daily dose of 6 mg per day per mouse (300 mg/kg body weight) (110). This dose of

36

metformin moderately reduced HFD-metabolic syndrome in Swiss-Webster mice (Fig S3.7.4)
but had only slight impacts in C57BL/6 mice (Fig S3.7.5), in which the above studies and most
work in this model has been performed. Hence, we selected a higher dose of oral metformin, 30
mg per day per mouse, which was well tolerated and clearly reduced many aspects of HFDinduced metabolic syndrome, including weight gain, increased adiposity, and hyperglycemia
(Fig 3.6.4). Antibiotics did not reduce such ability of metformin to reduce HFD-induced
increases in weight gain, adiposity, and hepatic steatosis (Fig 3.6.4A-D and S3.7.6). In accord
with the notion that HFD-induced dysglycemia is itself mediated in part by microbiota,
administration of antibiotics ameliorated, by themselves, HFD-induced dysglycemia as assessed
by measure of fasting glucose, thus obscuring our ability to measure if metformin would prevent
HFD-induced dysglycemia in absence of microbiota (Fig 3.6.4E). Nonetheless, under antibiotic
treatment, metformin still improved glucose tolerance following 3 weeks and 8-weeks of HFD
exposure (Fig 3.6.4F&G). Ability of metformin to reduce glucose levels was not, irrespective of
antibiotics, associated with any adverse effects or general signs of ill health, which can itself
lower blood glucose. Nor did metformin result in any markers of inflammation that can occur
from drug toxicity, nor did antibiotics appear to impact the extent to which metformin reduced
low-grade inflammation in that metformin treatment modestly but broadly reduced expression of
a panel of indices of low-grade inflammation (Fig 3.6.4H-J). Overall, a similar pattern was seen
in a distinct strain of mice (Swiss-Webster), in that while metformin had only modest reduced
HFD-induced metabolic syndrome in these mice, antibiotics did not reduce that effect (Fig
S3.7.4). Hence, analogous to the case for metformin administered by the IP route, use of
antibiotics to reduce levels of microbiota did not yield data to support the notion that microbiota
plays a key role in this drug’s ability to ameliorate metabolic syndrome.
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One potential explanation for inability of antibiotics to suppress metformin’s
amelioration of HFD-induced metabolic syndrome is that, despite broad suppression of total
bacterial loads, perhaps select bacteria can bloom. We explored this possibility focusing on
Proteobacteria, a phyla in which we (Fig 3.6.2) and others have observed contains much of the
taxa enriched by metformin treatment (111, 124). We observed that while antibiotics suppressed
increases in -Proteobacteria, increased  and proteobacteria were observed in metformintreated mice amidst antibiotic treatment (Fig S3.7.7). While it is difficult to discern if such
changes contributed to metformin’s action in these conditions, this result serves as an example of
the general limitation of investigating the role of the microbiota via antibiotics. Indeed,
antibiotics reduce but do not eliminate gut bacteria and can select for gut bacteria, such as those
that populate inner mucus that may have an outsize impact on low-grade inflammation and hence
metabolic syndrome. Hence, we next used germfree mice as a means to examine the extent to
which metformin might ameliorate HFD-induced metabolic syndrome in a host completely
lacking gut bacteria. A technical limitation to germfree mice is that it is very difficult to
track/monitor metabolic parameters without compromising the germfree state. Hence, groups of
age-matched germ-free mice were split into 3 groups, visually assessed to be of similar body
mass and administered autoclaved grain-based chow, irradiated HFD (IR-HFD), which we’ve
shown does not compromise germfree status, or IR-HFD and oral metformin (filter sterilized) via
drinking water (129). In accord with the notion that microbiota may be more important for HFDinduced dysglycemia than obesity per se, under germfree conditions, IR-HFD still induced clear
increases in weight and adiposity but induced only minimal dysglycemia (Fig 3.6.5), in accord
with our recent work (123). While such minimal dysglycemia precluded ability of metformin to
correct it, metformin still clearly diminished the extent of adiposity induced by IR-HFD (Fig
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3.6.5 and S3.7.5) albeit not to the extent observed in conventional mice (Fig 3.6.4C). Metformin
also continued to reduce hepatic steatosis in germfree mice (Fig 3.6.5 and S3.7.8 D).
Additionally, metformin-treated mice showed a trend to a trend , albeit not statistically
significant, toward reduced insulin levels, which, together with the slight trend toward reduced
glucose, in accord with notion that metformin’s ability to sensitize response to insulin remained
intact. Metformin’s sensitization of insulin signaling is proposed to be related to its activation of
AMPK. Hence, we analyzed metformin’s impact on levels of Phospho-AMPK in livers of HFDfed mice in conventional and GF mice. In accord with widely reported notion that metformin
activates AMPK (112), and that AMPK activity is elevated in GF mice (100), we observed
induction, albeit variable, of phospho-AMPK in conventional mice and elevated basal phosphoAMPK in GF mice (Fig S3.7.8 C). We did not observe any additional induction of phosphoAMPK in metformin-treated GF mice. We view these results as being in accord with the notion
that activation of phosphor-AMPK might be an important even in conventional mice but that
additional actions of metformin drive its impacts in GF mice. More generally, metformin
continued to broadly ameliorate an array of indices of low-grade inflammation that were induced
by IR-HFD. Specifically, metformin ameliorated colon shortening and reduced expression of
MCP-1, IL-6, CXL-1, and TNF in colon, liver and adipose tissue (Fig 3.6.4). Together, these
results support the notion that metformin has anti-inflammatory activity, irrespective of gut
microbiota, which may not be required for this drug to ameliorate metabolic syndrome.
3.5

Discussion
Metformin is amongst the world’s most widely prescribed drugs, largely due to its ability

to effectively treat early-stage type 2 diabetes and, moreover, ameliorate many of the metabolic
abnormalities collectively referred to as metabolic syndrome, that are associated with
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dysglycemia (128). Limitations of metformin include limited potency and some gastrointestinal
dysfunction including nausea and diarrhea in some patients. Hence, there has long been interest
in understanding mechanisms by which metformin acts, as such knowledge might allow design
of better treatments for metabolic syndrome. While an array of potential mechanisms that
contribute to metformin’s action have been proposed, the extent to which such mechanism are
crucial contributors to this drug’s beneficial effects are less clear, nor have direct targets of
metformin been convincingly defined.
Considering the recent extensive appreciation that gut microbiota contribute mightily to
numerous aspects of host health, including the view promulgated by ourselves and others that
microbiota dysbiosis drives low-grade inflammation that promotes metabolic syndrome (104), it
is not surprising that multiple research groups hypothesized that metformin might impact gut
microbiota in a manner that might contribute to metformin’s beneficial effects (118). That, in
both rodents and humans, metformin’s beneficial effects were associated with alterations in the
microbiome supported this notion (116, 124, 127). However, since the conditions that metformin
treats are, themselves, associated with alterations in gut microbiota composition, such results
could also reflect metformin ameliorating metabolic syndrome resulting in changes in gut
microbiota. That transplant of microbiota from metformin-treated hosts to mice not exposed to
this drug conferred beneficial metabolic effects suggests metformin-induced changes in
microbiome are not purely a consequence of treatment benefits (124), but is also consistent with
the possibility that such changes are both a cause and consequence of amelioration of metabolic
syndrome. Our observation that metformin impacted the microbiota in a manner that reduced its
encroachment into the mucus is in accord with this paradigm, but yet none of these findings
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address the extent to which presence of a gut microbiota is necessary for metformin’s beneficial
effects.
A central tenet in the microbiota field is that if the microbiota plays a crucial role in the
process by which a particular intervention causes a phenotype, that intervention should not
induce that phenotype in the absence of microbiota. For example, many interventions that cause
colitis in conventional conditions are without effect in germfree conditions (114). Another
example of this tenet is our work that synthetic dietary emulsifiers that cause mucus thinning and
low-grade inflammation and metabolic syndrome in conventional conditions, cause none of these
in germfree mice indicating that these events are fully microbiota dependent (105). Such
appreciation of the importance of the microbiota in low-grade inflammation and metabolic
syndrome led us to hypothesize that metformin would fail to impact metabolic syndrome in the
absence of microbiota. However, our data did not support this hypothesis. Rather, neither
antibiotics or germfree approaches prevented the ability of metformin to ameliorate metabolic
syndrome. In particular, irrespective of whether microbiota were present, metformin attenuated
HFD-induced low-grade inflammation, glucose intolerance, adiposity, and hepatic steatosis.
While many of the impacts of metformin in micro-ablated mice could be the result of reduced
adiposity, the observation that it also prevented indices of low-grade inflammation in the gut are
in accord with suggestions that metformin’s anti-inflammatory activity is central to its beneficial
effects. Indeed, metformin is now recognized to have fairly broad anti-inflammatory effects
(119), and our results herein are consistent with the possibility that such effects contribute to
metformin’s protection against diet-induced metabolic syndrome.
A major caveat of our results is that one of the central features of metabolic syndrome,
namely dysglycemia, was itself clearly reduced by reducing/eliminating microbiota, thus
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obscuring our ability to examine how metformin impacted it in these conditions. Another caveat
of our findings is that effective doses of metformin in mice are higher than that used in humans,
and thus might possibly be mediated by distinct mechanisms. Indeed, although mice exhibited no
behavioral, histopathologic, or other indicators of any ill effects from oral or intraperitoneal
metformin, we cannot rule out the possibility that some type of subtle toxicity reduced adiposity,
which led to the reductions in the metabolic/inflammatory parameters we measured. Lastly, we
note that the extent to which metformin ameliorated HFD-induced adiposity was less in GF mice
relative to antibiotic-treated mice suggesting that metformin-induced changes in microbiota in
antibiotic-treated mice might contribute to its efficacy therein. Such caveats notwithstanding, we
submit that the most reasonable and simplest explanation for existing data, and our results herein,
is a scenario wherein metformin’s ability to ameliorate metabolic syndrome results in alterations
in gut microbiota that alleviate low-grade inflammation and subsequently further alleviates, and
maintains alleviation of, metabolic syndrome. In support of this possibility, we note that other
means of inducing dysglycemia, for example islet toxin streptozotocin, also induce microbiota
dysbiosis and promotes microbial breach of the gut barrier and interventions that ameliorate such
dysglycemia will reduce the associated dysbiosis (117, 122, 127).
The notion that the beneficial impact of metformin on gut microbiota might be indirect
does not preclude the possibility that such effects are important to the efficacy of the drug in its
real usage wherein a microbiota is present. Indeed, amelioration of dysbiosis and microbiota
encroachment may be critical to the lasting efficacy of this compound. By analogy, a weight loss
intervention might facilitate the ability of a person to exercise, which is then critical for sustained
efficacy of the intervention. Extending the analogy, transfer of exercise phenotype by itself may,
like a fecal microbiota transplant, recapitulate many of the benefits of the original intervention.
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Thus, we do not question the conclusion of the array of studies that indicate that metformin
ameliorates microbial dysbiosis and that such effects are important to the drug’s beneficial
metabolic effects. Yet, we suggest the gut microbiota is not germane to identifying the direct
targets and primary mechanism of action of metformin.
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3.6

Figures and legends

Figure 1 Metformin ameliorates HFD-induced metabolic syndrome.
6-week old male C57 BL/6 mice (n=10 per condition) were maintained on a standard grain-based
chow diet or administered a western style low-fiber high-fat diet (HFD) for 12 weeks. HFD-fed
mice were injected IP with saline (NS) or metformin (metf) daily from 2 weeks post-diet
exposure until being euthanized. Weight (A) and Body composition (B) was monitored. (C)
Epididymal fat pad pass measured post-euthanasia. (D) Mice were fasted for 5h every 4 weeks
and blood glucose measured. (E) Colon length measured post-euthanasia. (F) Serum MCP-1
measured by ELISA following 8 weeks HFD exposure and overnight fasting. (G) Representative
H&E stained liver sections. (H) Histologic scoring of liver sections for extent lipid
accumulation. Data are shown as mean +/- SEM; * indicates statistical significance (p < 0.05) by
Student’s t-test for HFD/metformin vs HFD/NS.
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Figure 2 Metformin impacts microbiota composition and reduces microbiota
encroachment.
6-week old male C57 BL/6 mice (n=10 per condition) were HFD for 12 weeks. HFD-fed mice
were injected IP with saline (NS) or metformin (metf) daily from 2 weeks post diet exposure
until being euthanized. (A) Comparison of fecal microbiome composition via Principal
coordinate analysis (PCoA) of the UniFrac coordinates following week 2 and 12 weeks; 0 and 10
weeks post-metformin treatment. (B)The histogram shows Linear discriminant analysis (LDA).
(C) Rarefaction curves of number of observed OTUs based on sequence similarities for control
and treatment group at week 2 and week 12. (D) Confocal microscopy analysis of microbiota
localization; Muc2 (green), actin(purple), bacteria (red), and DNA (Blue). Bar= 20μm. (E)
Distance of closest bacteria to intestinal epithelial cells (IEC) per condition over 5 high-powered
field per mouse. Pictures are representatives of 10 biological replicates.
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Figure 3 Amelioration of HFD-induced metabolic syndrome in antibiotictreated mice.
6-week old male C57 BL/6 mice (n=10 per condition) were fed HFD for 12 weeks.
HFD-fed mice were injected IP with saline (NS) or metformin (metf) daily from 2
weeks post diet exposure until being euthanized, with or without antibiotic (Ab) in
drinking. (A) PCR- based quantification of bacterial load adhered to feces on week 4
and 12. (B) Body weight (C) MRI and analyzing body composition every 4 weeks.
(D) Epididymal fat pad pass measured post-euthanasia. (E) Histologic scoring of
section of liver (F) Mice were fasted for 5h every 4 weeks and blood glucose
measured. (G) Serum MCP-1 measured by ELISA following 12 weeks HFD exposure
and overnight fasting. (H-I) The mRNA was extracted from fat and expression level
of MCP-1 and TNF was analyzed by RT-PCR (J) Colon length measured posteuthanasia. Data are shown as mean +/- SEM; * indicates statistical significance (p <
0.05) by Student’s t-test for HFD/metformin vs HFD/NS. (K) PCoA plot combining
terminal parameters of weight, fat composition, fat pad mass, blood glucose, MCP-1,
and colon length.
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Figure 4 Efficacy of oral metformin amidst antibiotics.
6-week old male C57 BL/6 mice (n=5 per condition) were maintained on a western
style low-fiber high-fat diet (HFD) for 8 weeks. HFD-fed mice were administered
drinking water containing metformin (10 mg/ml) or vehicle control from first week of
study, with or without antibiotics (ABX) in drinking water. (A) Body weight (B) MRI
and analyzing body composition (C) Epididymal fat pad pass measured posteuthanasia (D) Histologic scoring of section of liver (E) Mice were fasted for 5h every
4 weeks and glucose was measured. (F-G) Glucose measured after 0, 30, 60, and 90
min after interperitoneally injected with glucose at week 3 (F) and week 8 (G). (H)
The mRNA was extracted from adipose and expression level of MCP-1. (I) CXCL1
(J) and TNF was measured by RT-PCR. (K) Fecal lipocalin-2 measured by ELISA
at 8-week timepoint. Data are shown as mean +/- SEM; * indicates statistical
significance (p < 0.05) by Student’s t-test for HFD/metformin vs HFD Control.
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Figure 5 Maintained efficacy of metformin in HFD-fed germfree mice.
6-week old male C57 BL/6 mice (n=5 per condition) were maintained on autoclaved chow or
irradiated HFD (IR-HFD) for 8 weeks while being administered drinking water containing
metformin (10 mg/ml) or vehicle. All parameters were measured following euthanasia. Body
weight and epididymal fat pad. Histologic scoring of section of liver. Mice were fasted overnight
and blood glucose and insulin was measured. The colon length and spleen weight measured.
Serum MCP-1 measured by ELISA and overnight fasting. The mRNA was extracted from colon
and expression level of MCP-1, IL-6, CXCL1 and TNF was analyzed by RT-PCR. The mRNA
was extracted from adipose and expression level of MCP-1 and TNF was analyzed by RT-PCR.
The mRNA was extracted from liver and expression level of MCP-1 and CXCL1 was analyzed
by RT-PCR. The mRNA was extracted from adipose and expression level of MCP-1 and TNF
was analyzed by RT-PCR. Data are shown as mean +/- SEM; * indicates statistical significance
(p < 0.05) by Student’s t-test for HFD/metformin vs. HFD.
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3.7

Supplemental Figures and Legends

Figure 6(relates to Figs 1, 3, and 4).
Data are raw unnormalized mouse weights used to generate corresponding figures
showing relative changes in weight in main figures.

.
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Figure 7(relates to Fig 2).
Impact of metformin on gut microbiota composition. Additional analysis on fecal microbiome
sequencing data from Fig 2. The bar graph represents relative abundance of bacteria at the
phylum level at post treatment and terminal point. Linear discriminant analysis Effect Size
(LEfSe) of gut microbiota changes following consumption of HFD vs HFD/NS. The
phylogenetic tree shows LDA scores calculated for different microbiome abundance between
treated mice with metformin versus saline.
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Tissues samples from mice described in Fig 3 were subjected to histopathologic
analysis. Liver and adiposity were H&E stained. Picture are representatives of 10 biological
replicates.
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Figure 8(relates to Fig 4).
Efficacy of oral metformin amidst antibiotics in Swiss-Webster mic. 6-week old male
Swiss Webster mice (n=5 per condition) were maintained on a western style low-fiber
high-fat diet (HFD) for 12 weeks. HFD-fed mice were administered drinking water
containing metformin (3 mg/ml) or vehicle control from first week of study, with or
without antibiotics (ABX) in drinking water. (A) Body weight (B) MRI and analyzing
body composition (C) Epididymal fat pad pass measured post-euthanasia (D) Mice
were fasted for 5h every 4 weeks glucose was measured Data are shown as mean +/SEM; * indicates statistical significance (p < 0.05) by Student’s t-test for
HFD/metformin vs HFD.
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Figure 9(related to Fig 4).
Effect of lower dose oral metformin in C57BL/6 mice. 6-week old male C57 BL/6 mice (n=10
per condition) were maintained on a western style low-fiber high-fat diet (HFD) for 12 weeks.
HFD-fed mice were administered drinking water containing metformin (3 mg/ml) or vehicle
control from first week of study, with or without antibiotics (ABX) in drinking water. (A) Body
weight (B) MRI and analyzing body composition (C) Epididymal fat pad pass measured posteuthanasia (D) Mice were fasted for 5h every 4 weeks glucose was measured. (E) Colon length.
(F) Serum MCP-1. Data are shown as mean +/- SEM; * indicates statistical significance (p <
0.05) by Student’s t-test for HFD/metformin vs HFD.
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Figure 10 (relates to Fig 4).
Efficacy of oral metformin amidst antibiotics. Tissues samples from mice described in Fig 4
were subjected to histopathologic analysis. Liver and adiposity were H&E stained. Picture are
representatives of 10 biological replicates.
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Figure 11 (relates to Fig 4).
Impact of metformin on Proteobacteria amidst antibiotic treatment. Fecal samples were
collected from mice in figure 4, at 8-week timepoint, DNA extracted and subjected to qPCR
using universal 16S primers or primers specific for indicated family of Proteobacteria. Familyspecific PCR values expressed as relative to total level of bacteria. Data are shown as mean +/SEM; * indicates statistical significance (p < 0.05) by Student’s t-test for HFD/metformin vs
HFD.
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Tissues samples from mice described in Fig 5 were subjected to further analysis. (A)
Inguinal subcutaneous fat mass. (B) Scapula brown fat mass. (C) Liver extracts were analyzed
by SDS-PAGE immunoblotting. (D) Liver and adiposity were H&E stained. Picture are
representatives of 10 biological replicates.
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4 CONCLUSION
The murine intestine normally contains about 1014 microorganisms, mainly residing in the colon.
The gram-negative Bacteriodetes and the gram-positive Firmicutes are the most common phyla
in human and mouse (131). The gram-negative Verrucomicrobia, Proteobacteria, Spirochaetes,
and Tenericutes, as well as the gram-positive Actinobacteria, are also found in the gut of
mammals. In the upper parts of the intestine, such as the ileum, Firmicutes are the dominant
species; however, a considerable amount of the bacteriodetes fraction and some Actinobacteria
could also be found. In the caecum, on the other hand, the Proteobacteria, including the
Enterobacteriaceae are present and thus, the most diverse microbiota with different types of
phyla could be found in the feces.
Microbiota may be removed by two means, namely the use of antibiotics and germfree
mice. Antibiotic approaches provide only a partial removal of the microbiota but offer logistical
ease and the advantage that the mice are generally immunologically normal. In contrast, germ
free approaches are laborious and yield mice with a poorly developed immune system but
provide complete and total absence of microbiota.
The Gordon group first reported that the germfree mice gained weight after colonization
with bacteria from the lower gut of conventionally raised mice (133). They also reported that
C57BL/6J mice in GF environment are resistant to obesity; therefore, HFD induced obesity is,
itself dependent upon the presence of microbiota. (100-132)
My advisor’s lab found that HFD in the bacterial milieu, reduces mucus thickness and
decreases the bacterial-epithelial distance that, together, drive host inflammatory signaling. Thus,
I expected that, unlike conventional mice, germ-free mice that consumed metformin would not
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show a reduced risk of HFD-induced metabolic syndrome. However, we observed completely
opposite results.
To better investigate treatments for obesity and type 2 diabetes, metabolic profiling will
help us study obesity mechanisms by investigating the involved pathways or processes.
Consequently, we know inflammation is associated with both chronic and acute diseases and so
is obesity. Moreover, this is the changes that people see about inflammation regarding the
metabolites and proteins and the omic interactions, often referred to as the inflammasome. I
envision that future studies can use mass spectrometry to perform a targeted quantitative analysis
of metabolites, as the microbiota generates secondary chemicals from not absorbed food or body
secretions such as bile salts. These are absorbed by the gut and can be detected in blood and
urine. The alteration of the microbiota is associated with changes in the metabolome; this profile
can be applied agnostically to figure out which metabolites are associated with which conditions
regarding obesity.
Studying these metabolic profiles and signatures earlier than other conventional techniques can
help us identify the risk of obesity or obesity-related diseases or even pre-obesity. Alternatively,
it can help us realize which treatment works better for different groups of patients. In other
words, metformin is reported in the current study as a concept from the larger perception, known
as pharmacometabonomics. Using these findings, one can predict from a pre-dose or preintervention baseline metabolic signature how a person will react either to disease or drugs or
therapy. Finally, it is important to point out that variation in human populations can
accommodate. Obesity does not have a single cause and variability, although it is a distraction by
many people, can actually identify individuals or groups of individuals who have a slightly
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different metabolic response and we can use this variation to try and really home in on pathways
that may be important in obesity and move towards the concept of personalized medicine.

Also, other approaches specific to what we utilized in investigating metformin are include
gnotobiotic mice with limited microbiota such as mice with an altered Schaedler flora (ASF).
The advantages of utilizing ASF mice instead of Germ-Free animals is their better developed
immune system and metabolic capabilities. Another alternative is depleting of the microbiota
with antibiotics post-weaning. However, these alternatives have their own disadvantages which
do not allow us to fully understand the effects of metformin on HFD. For instance, the limited
microbial diversity in ASF mice will not fully recapitulate the milieu in a human microbiota
perturbed by a high-fat low-fiber diet.
Another potential follow up approach would be to utilize in ex-vivo to determine if
metformin promotes the growth of bacteria in our gut directly via providing energy or another
substrate beneficial to certain taxa. While also elucidating the interactions with host physiology
and immune system development and response. Further, transfer the ex-vivo microbiome to
Germ-Free hosts with the intention of studying the effects a metformin perturbed microbiota may
have on a host. In our study we did not see significant changes in germ-free mice. However, this
does not mean that metformin perturbed microbiota transferred to germ free host will not induce
distinctive effects. Transfer of feces, ex-vivo and small intestinal material to hosts will best
illuminate the role microbiota may play in metformin’s protective effects.
In conclusion, much work is needed to fill gaps of knowledge. Better understanding of
these pathways will allow better treatments for the prevention and cure of obesity. I hope the
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information uncovered by this project will constitute one small step towards the bettering of
human health.
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